U.S. regulators on April 1 approved an obesity pill called Foundayo from Eli Lilly, adding a second option for consumers who want to take weight loss drugs but desire to avoid injections.
Foundayo is a glucagon-like peptide-1 (GLP-1) medication meant to be taken once a day.
“We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications,” David Ricks, chair and CEO of Eli Lilly, said in a statement.
“As a convenient, once-daily oral pill that delivers meaningful weight loss, this is obesity care designed for the real world.”…